Susquehanna Portfolio Strategies’s Fate Therapeutics FATE Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$913K	Buy	+338,058	New	+$626K	0.01%	569

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna Portfolio Strategies's FATE Position: Q2 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Fate Therapeutics (FATE) in Q2 2026: 338,058 shares worth $913K. The stake represents 0.01% of the portfolio and ranks #569 among its holdings.

155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Susquehanna Portfolio Strategies held 338,058 shares of Fate Therapeutics worth $913K as of Q2 2026.
Fate Therapeutics was a new Susquehanna Portfolio Strategies position in Q2 2026.
Fate Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #569 holding.
155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.